New immune therapy trial offers hope for children with aggressive bone cancer
NCT ID NCT07428993
Summary
This study is testing whether adding a new immune therapy called CAR-T cells after standard chemotherapy can help prevent cancer from returning in children with high-risk osteosarcoma (bone cancer). Researchers will enroll 41 children who have completed their initial chemotherapy and surgery. The main goal is to see if this additional treatment improves survival without cancer recurrence over the following year.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PEDIATRIC OSTEOSARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
St. Jude Children's Research Hospital
Memphis, Tennessee, 38105-2794, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.